C
Chul Ho Kim
Researcher at Korea Research Institute of Bioscience and Biotechnology
Publications - 132
Citations - 2503
Chul Ho Kim is an academic researcher from Korea Research Institute of Bioscience and Biotechnology. The author has contributed to research in topics: Fermentation & Levansucrase. The author has an hindex of 26, co-authored 130 publications receiving 2187 citations.
Papers
More filters
Journal ArticleDOI
Statistical optimization of medium for the production of recombinant hirudin from Saccharomyces cerevisiae using response surface methodology
TL;DR: An efficient fermentation medium producing a colourless product with high yields has been developed for the production of recombinant hirudin from Saccharomyces cerevisiae using response surface methodology to optimize the medium constituents.
Journal ArticleDOI
Sequential acid-/alkali-pretreatment of empty palm fruit bunch fiber.
TL;DR: Results indicate that the sequentially acid/alkali-pretreated EPFBF could be broadly useful as a novel biomass.
Journal ArticleDOI
Bioethanol production using the sequential acid/alkali-pretreated empty palm fruit bunch fiber.
Seonghun Kim,Chul Ho Kim +1 more
TL;DR: In this paper, a sequential acid/alkali pretreatment strategy was applied to increase the fermentable sugar in empty palm fruit bunch (EPFB) fiber, which was effectively increased by using dilute sulfuric acid treatment to eliminate hemicellulose followed by highly concentrated sodium hydroxide treatment for delignification.
Journal ArticleDOI
A novel autonomously replicating sequence (ARS) for multiple integration in the yeast Hansenula polymorpha DL-1.
Jung Hoon Sohn,Eui Sung Choi,Chul Ho Kim,M O Agaphonov,M D Ter-Avanesyan,J S Rhee,Sang Ki Rhee +6 more
TL;DR: Several autonomously replicating sequences of Hansenula polymorpha DL-1 with the characteristics of tandem integration were cloned by an enrichment procedure and analyzed for their functional elements to elucidate the mechanism of multiple integration in tandem repeats.
Journal ArticleDOI
Current status of the anticoagulant hirudin: its biotechnological production and clinical practice
TL;DR: Hirudin may expand its therapeutic utility over heparin in the near future after 10 years of clinical applications and two recombinant hirudins and a hirUDin analogue have gained marketing approval from the United States Food and Drug Administration.